Biocept Inc : Biocept appoints Timothy Kennedy as chief financial officer and senior vice president of operations . Timothy Kennedy succeeds Mark Foletta as CFO .Biocept Inc says Mark Foletta will remain as a consultant to company, beginning in September 2016.
Rti Surgical Inc : RTI Surgical announces 2016 second quarter results . RTI surgical Inc says management and board of directors are launching a comprehensive strategic review of company's business lines . FY2016 earnings per share view $0.19, revenue view $284.1 million -- Thomson Reuters I/B/E/S . Q2 revenue $67.6 million versus i/b/e/s view $66.5 million . Sees FY 2016 adjusted earnings per share $0.09 to $0.12 excluding items . Sees FY 2016 earnings per share $0.03 to $0.06 . Sees FY 2016 revenue $274 million to $280 million . Sees q2 2016 earnings per share $0.09 to $0.12 excluding items . Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S . RTI surgical inc says achieved q2 worldwide direct revenues of $39.6 million, a 16 percent increase over q2 of 2015 .RTI Surgical Inc says intends to engage a management consulting firm to assist with strategic review.
LabStyle Innovations Corp :Labstyle Innovations Corp says it is changing its corporate name to DarioHealth Corp.
Tempus Holdings Ltd <6880.HK>: Hold-voluntary announcement - the acquisition of equity interest in Tempus jinyuan limited <6880.HK> . Oto (bvi) investment limited, unit of co, entered into an agreement with an independent third party and Tempus jinyuan . Agreement in relation to acquisition of 36% of issued share capital of target co and subscription of new shares of target company . Oto bvi agreed to purchase 36% of issued share capital of target company at consideration of RMB7.2 million . Oto bvi to inject RMB10.0 million in cash into target co in consideration of target co allotting and issuing new shares of target co to oto bvi .
Amplifon SpA : H1 revenues 544.2 million euros ($598.67 million), up 10.6 percent year on year at constant exchange rates . H1 EBITDA net of non-recurring expenses 88.0 million euros, up 12 percent year on year . H1 EBITDA 85.5 million euros versus 71.8 million euros a year ago . H1 net profit 29.6 million euros versus 18.5 million euros a year ago .For the rest of 2016 the company expects the positive trend in sales and profitability to continue thanks to solid organic growth and the continuous network expansion.
Globus Medical Inc : Preliminarily projects 2017 full year sales of $640M including $40M from acquisition . FY2016 earnings per share view $1.20, revenue view $583.1 million -- Thomson Reuters I/B/E/S . Globus Medical reports second quarter 2016 results . Q2 non-gaap earnings per share $0.29 . Q2 earnings per share $0.27 . Q2 earnings per share view $0.29 -- Thomson Reuters I/B/E/S . Sees FY 2016 sales about $575 million . Q2 revenue $137.5 million versus I/B/E/S view $141.8 million .Sees full year 2016 gaap earnings per share of approximately $1.17.
C R Bard Inc : Sees FY 2016 adjusted earnings per share $10.10 to $10.20 . Bard announces second quarter results . Q2 earnings per share $2.11 . Sees FY 2016 sales up 7 to 8 percent . Q2 sales $931.5 million versus i/b/e/s view $915.2 million . Q2 earnings per share view $2.47 -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $10.15, revenue view $3.65 billion -- Thomson Reuters I/B/E/S.
NuVasive Inc : FY2016 earnings per share view $1.51, revenue view $936.0 million -- Thomson Reuters I/B/E/S . NuVasive reports second quarter 2016 financial results . Q2 non-GAAP earnings per share $0.40 . Q2 GAAP earnings per share $0.57 . Q2 revenue rose 16.4 percent to $236.2 million . Sees 2016 revenue of approximately $962.0 million . Sees 2016 non-GAAP diluted earnings per share of approximately $1.64 .Sees 2016 non-GAAP operating profit margin of approximately 16.0 pct.
Utah Medical Products Inc : Utah Medical Products Inc qtrly net sales $10.5 million versus $10.4 million . Reports financial performance for second quarter 2016 . Q2 earnings per share $0.86 . Says looking forward, sales in 3Q 2016 may be $800 lower than in either 1Q or 2Q 2016 .Expect higher 3Q 2016 domestic direct sales compared to 2Q 2016.
Tandem Diabetes Care Inc : Fda clearance of an expanded pediatric indication for t:slim insulin pump .Expanded pediatric indication of t:slim insulin pump for ages 6 and older.